黄药子治疗Graves病有效性和安全性的研究进展

doi:10.16138/j.1673-6087.2024.04.11

摘要/Abstract

摘要：

甲状腺功能亢进症以弥漫性毒性甲状腺肿（Graves disease, GD）最多见，传统的抗甲状腺药物往往难以取得满意的功效，复发率高、疗程长是最为突出的缺点。中药黄药子具有“消瘿”的功效，近年被广泛用于治疗GD，但长期使用可能会导致肝功能和肾功能损害。故黄药子治疗GD的有效性和安全性需更多研究。

关键词: 黄药子, Graves病, 有效性, 安全性, 薯蓣皂苷元, 肝毒性

Abstract:

Hyperthyroidism is most common in Graves disease (GD), and traditional antithyroid medicine are often difficult to achieve satisfactory efficacy, and high recurrence rate and long course of treatment are the most prominent problems. Huangyaozi（Dioscorea bublifera L.）, a traditional Chinese medicine, has the effect of “Xiao Ying” and has been widely used in the treatment of GD in recent years, but long-term use may cause liver and kidney damage. Therefore, more research on the efficacy and safety of Huangyaozi need to be done in the treatment of GD.

Key words: Dioscorea bublifera L., Graves disease, Efficacy, Safety, Diosgenin, Hepatotoxicity

中图分类号:

R581.1

崔依帆, 张瑞祥, 韦晓, 刘超. 黄药子治疗Graves病有效性和安全性的研究进展[J]. 内科理论与实践, 2024, 19(04): 273-277.

CUI Yifan, ZHANG Ruixiang, WEI Xiao, LIU Chao. Study on efficacy and safety of Dioscorea bublifera L. in treatment of Graves disease[J]. Journal of Internal Medicine Concepts & Practice, 2024, 19(04): 273-277.

参考文献 28

[1]	Davies TF, Andersen S, Latif R, et al. Graves’ disease[J]. Nat Rev Dis Primers, 2020, 6(1):52. doi: 10.1038/s41572-020-0184-y pmid: 32616746
[2]	中华医学会内分泌学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会核医学分会, 等. 中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J]. 国际内分泌代谢杂志, 2022, 42(5): 401-450.
[3]	Salmaso C, Bagnasco M, Pesce G, et al. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto’s thyroiditis and Graves’ disease[J]. Ann N Y Acad Sci, 2002,966:496-501.
[4]	张莉莉, 韦宇, 方心怡, 等. 夏枯草、黄药子、五味子治疗甲状腺功能亢进症经验 ——仝小林三味小方撷萃[J]. 吉林中医药, 2020, 40(5): 568-570.
[5]	巴明玉, 余丹丹, 王娴, 等. 燕树勋应用黄药子治疗甲状腺疾病经验[J]. 河南中医, 2021, 41(5): 719-721.
[6]	朱大诚, 徐丽婷, 徐笑明. 黄药子化学成分研究进展[J]. 江西中医药大学学报, 2020, 32(2): 117-121.
[7]	朱大诚, 况东, 徐丽婷, 等. 黄药子药理作用及临床应用[J]. 中国老年学杂志, 2022, 42(1): 239-243.
[8]	陈红, 高水群, 肖锦仁, 等. 黄药子及其制剂致药物性肝损伤病例临床分析[J]. 湖南中医药大学学报, 2021, 41(9): 1442-1446.
[9]	黄智锋, 华碧春, 陈小峰, 等. 黄药子及其制剂致肝损害78例临床分析[J]. 中国实验方剂学杂志, 2013, 19(23): 295-297.
[10]	肖国勇. 复方甲亢汤治疗甲状腺功能亢进症的临床研究[J]. 中医临床研究, 2019, 11(33): 49-50.
[11]	田艳娟, 李万森, 高大红, 等. 抑亢丸联合丙硫氧嘧啶治疗甲状腺功能亢进症的疗效观察[J]. 现代药物与临床, 2020, 35(8): 1588-1591.
[12]	金华. 甲巯咪唑分别联合抑亢丸、夏枯草片治疗甲状腺功能亢进的效果比较[J]. 光明中医, 2019, 34(23): 3648-3650.
[13]	杨月, 姚晓文, 杨俊瑶, 等. 消瘿软坚散外敷联合甲巯咪唑治疗甲状腺功能亢进症的临床效果[J]. 中国当代医药, 2021, 28(33): 68-71.
[14]	洪振强, 高弘建, 赵诣, 等. 基于NF-κB信号通路的薯蓣皂苷元抗骨肉瘤作用机制研究[J]. 中华中医药杂志, 2018, 33(2): 748-752.
[15]	Bhardwaj N, Tripathi N, Goel B, et al. Anticancer activity of diosgenin and its semi-synthetic derivatives[J]. Mini Rev Med Chem, 2021, 21(13):1646-1665.
[16]	边德志, 胥柯, 黄飞, 等. 薯蓣皂苷元治疗Graves病大鼠的实验效果及相关机制研究[J]. 临床和实验医学杂志, 2018, 17(18): 1908-1911.
[17]	Bian D, Li Z, Ma H, et al. Effects of diosgenin on cell proliferation induced by IGF-1 in primary human thyrocytes[J]. Arch Pharm Res, 2011, 34(6):997-1005. doi: 10.1007/s12272-011-0617-y pmid: 21725821
[18]	Cai H, Wang Z, Zhang HQ, et al. Diosgenin relieves goiter via the inhibition of thyrocyte proliferation in a mouse model of Graves’ disease[J]. Acta Pharmacol Sin, 2014, 35(1):65-73. doi: 10.1038/aps.2013.133 pmid: 24241350
[19]	Mu S, Tian X, Ruan Y, et al. Diosgenin induces apoptosis in IGF-1-stimulated human thyrocytes through two caspase-dependent pathways[J]. Biochem Biophys Res Commun, 2012, 418(2):347-352.
[20]	Xin J, Cheng W, Yu Y, et al. Diosgenin from dioscorea nipponica rhizoma against Graves' disease-on network pharmacology and experimental evaluation[J]. Front Pharmacol, 2022,12:806829.
[21]	Zhang C, Zhang Q, Qin L, et al. Dioscin ameliorates experimental autoimmune thyroiditis via the mTOR and TLR4/NF-κB signaling[J]. Drug Des Devel Ther, 2023,17:2273-2285.
[22]	Zhang C, Qin L, Sun B, et al. Transcriptome analysis of the effect of diosgenin on autoimmune thyroiditis in a rat model[J]. Sci Rep, 2021, 11(1):6401. doi: 10.1038/s41598-021-85822-1 pmid: 33737640
[29]	Tan R, Hu Z, Zhou M, et al. Diosbulbin B: an important component responsible for hepatotoxicity and protein covalent binding induced by Dioscorea bulbifera L[J]. Phytomedicine, 2022,102:154174.
[30]	Li H, Peng Y, Zheng J. Dioscorea bulbifera L.-induced hepatotoxicity and involvement of metabolic activation of furanoterpenoids[J]. Drug Metab Rev, 2020, 52(4):568-584.
[31]	Ma Y, Niu C, Wang J, et al. Diosbulbin B-induced liver injury in mice and its mechanism[J]. Hum Exp Toxicol, 2014, 33(7):729-736. doi: 10.1177/0960327113506232 pmid: 24107456
[32]	Wu ZT, Li ZQ, Shi W, et al. The crucial role of metabolic regulation in differential hepatotoxicity induced by furanoids in Dioscorea bulbifera[J]. Chin J Nat Med, 2020, 18(1):57-69.
[33]	Zhang Y, Miao H, Guan H, et al. Long-term Diosbulbin B treatment induced liver fibrosis in mice[J]. Chem Biol Interact, 2019,298:15-23.
[34]	Lin D, Li W, Peng Y, et al. Role of metabolic activation in 8-Epidiosbulbin E acetate-induced liver injury[J]. Chem Res Toxicol, 2016, 29(3):359-366.
[35]	Shi W, Jiang Y, Zhao DS, et al. Metabolomic-transcriptomic landscape of 8-Epidiosbulbin E acetate -a major diterpenoid lactone from Dioscorea bulbifera tuber induces hepatotoxicity[J]. Food Chem Toxicol, 2020,135:110887.
[36]	巫晓慧, 王君明, 宋玲玲, 等. 炮制增强黄药子抗炎镇痛祛痰药效的实验研究[J]. 时珍国医国药, 2020, 31(11): 2649-2652.
[37]	巫晓慧, 王君明, 刘晨, 等. 炮制增强黄药子止咳功效并降低其毒性的研究[J]. 中国药学杂志, 2020, 55(10): 817-823. doi: 10.11669/cpj.2020.10.013
[38]	李俊, 肖瑶, 晏蔚田, 等. 黄药子肝毒性及减毒配伍研究进展[J]. 中华中医药学刊, 2020, 38(12): 100-103.
[23]	亓传旺, 咸建春. 黄药子、向天果、黑骨藤致肝损伤3例报告[J]. 临床肝胆病杂志, 2019, 35(12): 2780-2782.
[24]	岳树香, 张阳. 黄药子致肝损害1例[J]. 临床合理用药杂志, 2019, 12(22): 3.
[25]	王少珍, 廖联明. 黄药子中毒导致肝损伤的机制研究[J]. 中华卫生应急电子杂志, 2018, 4(1): 33-44.
[26]	孙雅馨, 秦红岩, 臧凯宏, 等. 黄药子致肝脏损伤的网络毒理学分析及验证[J]. 中国现代应用药学, 2021, 38(24): 3057-3063.
[27]	梁玉琼, 黄庆, 时乐, 等. 黄药子总皂苷对小鼠的肝毒性及其机制[J]. 中华中医药学刊, 2020, 38(10): 240-244.
[28]	马敏, 江振洲, 阮金兰, 等. 黄药子二萜内酯类成分对肝细胞毒性的验研究[J]. 中国天然药物, 2011, 9(4): 280-285.